论文部分内容阅读
目的:探讨养胃抗瘤冲剂联合新辅助化疗治疗中晚期胃癌患者的临床疗效。方法:将中晚期胃癌患者74例随机分为两组,每组各37例,对照组予行新辅助化疗方案,治疗组治以养胃抗瘤冲剂联合新辅助化疗方案,治疗后比较两组患者临床疗效、化疗后生存质量及不良反应发生率等指标,且治疗结束后进行为期3年的随访,并评价其3年生存率、局部复发率及远处转移率。结果:疗程结束,治疗组临床总有效率为62.2%,对照组为48.6%,治疗组高于对照组,且治疗组患者生活质量评分改善也优于对照组,差异均有统计学意义(P<0.05);治疗组不良反应发生率为59.5%,显著低于对照组78.4%,差异有统计学意义(P<0.05);随访结果提示治疗组3年生存率为56.7%,高于对照组的48.6%,差异有统计学意义(P<0.05);而两组患者局部复发率和远处转移率比较,差异无统计学意义(P>0.05)。结论:养胃抗瘤冲剂联合新辅助化疗治疗中晚期胃癌患者疗效确切,无明显增加不良反应发生率,有利于患者生活质量的提高,延长患者生存周期。
Objective: To investigate the clinical effects of Yangwei Kangao granules combined with neoadjuvant chemotherapy in the treatment of patients with advanced gastric cancer. Methods: 74 patients with advanced gastric cancer were randomly divided into two groups, 37 cases in each group. The control group received neoadjuvant chemotherapy. The treatment group was treated with Yangwei Kanguowu granules combined with neoadjuvant chemotherapy. After treatment, the patients in both groups were compared Clinical efficacy, quality of life after chemotherapy and incidence of adverse reactions and other indicators, and after the end of treatment for a 3-year follow-up, and evaluate its 3-year survival rate, local recurrence rate and distant metastasis rate. Results: At the end of treatment, the total clinical effective rate was 62.2% in the treatment group and 48.6% in the control group, the treatment group was higher than the control group, and the quality of life score of the treatment group was better than the control group (P <0.05). The incidence of adverse reactions in the treatment group was 59.5%, which was significantly lower than 78.4% in the control group (P <0.05). The follow-up results showed that the 3-year survival rate was 56.7% in the treatment group, (P <0.05). There was no significant difference between the two groups in the local recurrence rate and the distant metastasis rate (P> 0.05). Conclusion: Yangwei Kangao granules combined with neoadjuvant chemotherapy in the treatment of advanced gastric cancer patients with exact effect, no significant increase in the incidence of adverse reactions, is conducive to improving the quality of life of patients and prolong the life cycle of patients.